• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Helius Medical Technologies, Inc. Appoints Antonella Favit-Van Pelt, M.D., Ph.D. as Chief Medical Officer

    7/8/21 7:30:00 AM ET
    $TEVA
    $JNJ
    $BMY
    $HSDT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $TEVA alert in real time by email

    NEWTOWN, Pa., July 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ:HSDT) (TSX:HSM) ("Helius" or the "Company"), a neurotech company focused on neurological wellness, today announced the appointment of Antonella Favit-Van Pelt, M.D., Ph.D. to the position of Chief Medical Officer.

    "I am very pleased to welcome Dr. Favit-Van Pelt to Helius, who joins our team with a clinical and academic background in Neurology, as well as 20 years of experience advising and leading medical programs for healthcare companies – including both large, globally-diversified corporations and smaller, earlier-stage companies," said Helius CEO, Dane Andreeff. "I look forward to her future contributions as we continue our efforts to raise awareness of PoNS technology and its therapeutic benefits among clinicians, patients and payors in the U.S. market, while planning to enter the next phase of our clinical and regulatory strategy."

    "Helius is breaking new ground in the field of neurology with its PoNS technology, which has great potential as a non-invasive, non-drug therapy for patients suffering from a variety of chronic and debilitating neurological conditions," said Dr. Favit-Van Pelt. "I am excited to join Helius on the heels of its first U.S. regulatory clearance in multiple sclerosis and look forward to continuing the Company's recent market development, clinical and regulatory progress."

    Prior to joining Helius, Dr. Favit-Van Pelt led U.S. Medical Strategy for the Neurology program of H. Lundbeck A/S (LUN.CO, LUN DC, HLUYY), a global pharmaceutical company that specializes in the treatment of brain diseases, from 2018 to 2021. In this position, she oversaw the U.S. medical and life-cycle program activities related to therapies for movement disorders and epilepsy.

    In 2013, Dr. Favit-Van Pelt founded Synaerion Therapeutics ("Synaerion") and, in 2016, its affiliate Thera Neuropharma, Inc. ("Thera"), two privately-held biotechnology companies developing a small molecule regenerative therapy and RNAi-based integrated technology platform for ALS and traumatic brain injury ("TBI"). She oversaw all aspects of Synaerion's and Thera's management and strategy as Chief Executive Officer, President & Chairwoman of the Board from 2014 to 2017 and she continues to serve as President & Chairwoman. In 2009, she founded StratMedica, LLC, a privately-held company designed to provide corporate clients with contract senior management support. As Principal of StratMedica from 2009 to 2016, she directed clinical development and medical programs for eight healthcare companies, including Johnson & Johnson (NYSE:JNJ) and Teva (NYSE:TEVA). Dr. Favit-Van Pelt served as Senior Director and Global Medical Lead at Shire Pharmaceuticals (NASDAQ:SPHG) from 2007 to 2008, as Director of Medical Strategy at Bristol-Myers Squibb (NYSE:BMY) from 2005 to 2007, and as Global Clinical Development Lead at GE Healthcare (formerly Amersham Health) from 2001 to 2005.

    Dr. Favit-Van Pelt is a Board-certified neurologist who began clinical practice activity in 1994, with a focus on patients with rare neuromuscular disorders. She holds a graduate degree in Medicine and Surgery and a Ph.D. in Pharmacology from the School of Medicine and Surgery at the University of Catania, Italy.        

    As a material inducement to entering into employment with Helius, Dr. Favit-Van Pelt, who was not previously an employee or director of Helius, received options to purchase 18,000 shares of the Company's Class A common stock under Helius' Inducement Plan. The equity award under Helius' Inducement Plan was approved by the Company's independent directors in accordance with Nasdaq Listing Rule 5635(c)(4), which also requires a public announcement of equity awards that are not made under a stockholder approved equity plan.

    The options awards have an exercise price of $16.45 per share, the closing price of Helius' Class A common stock on July 7, 2021, the date of the grant. The options have a ten-year term and vest over a period of four years, with 25% vesting per year on the anniversary date of grant, provided Dr. Favit-Van Pelt's employment is continuing on each such date, and subject to acceleration or forfeiture upon the occurrence of certain events as set forth in Dr. Favit-Van Pelt's option agreement.

    About Helius Medical Technologies, Inc.

    Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company's purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. The Company's first commercial product is the Portable Neuromodulation Stimulator (PoNS™). For more information, visit www.heliusmedical.com.

    About the PoNS™ Device and PoNS Treatment™

    The Portable Neuromodulation Stimulator (PoNS™) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis ("MS") and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury ("mmTBI") and is to be used in conjunction with physical therapy. PoNS is an investigational medical device in the European Union ("EU") and Australia ("AUS"). It is currently under premarket review by the AUS Therapeutic Goods Administration.

    Cautionary Disclaimer Statement: 

    Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws. All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Forward-looking statements are often identified by terms such as "believe," "continue," "looking ahead," "will," "committed to," "goal," "expect," "remain," "hope" and similar expressions. Such forward-looking statements include, among others, statements regarding the Company's future strategic and operational execution, the next phase of the Company's market development activities, the Company's ability to spread awareness of of PoNS technology, clinical and regulatory development plans for the PoNS device, and the timing and success of the Company's commercialization efforts in the United States.

    These statements involve substantial known and unknown risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those expressed or implied by such statements. Important factors that could cause actual results to differ materially from the Company's expectations include uncertainties regarding the Company's capital requirements to achieve its business objectives, the impact of the COVID-19 pandemic, the Company's ability to train physical therapists in the supervision of the use of the PoNS Treatment, the Company's ability to secure contracts with rehabilitation clinics, the Company's ability to obtain national Medicare coverage and to obtain a reimbursement code so that the PoNS device is covered by Medicare and Medicaid, the Company's ability to build internal commercial infrastructure, market awareness of the PoNS device, future clinical trials and the clinical development process, manufacturing and supply chain risks, potential changes to the MCIT program, the product development process and FDA regulatory submission review and approval process, other development activities, ongoing government regulation, and other risks detailed from time to time in the "Risk Factors" sections of the Company's Annual Report on Form 10-K for the year ended December 31, 2020, its Quarterly Report on Form 10-Q for the quarter ended March 31, 2021 and its other filings with the United States Securities and Exchange Commission and the Canadian securities regulators, which can be obtained from either at www.sec.gov or www.sedar.com.The reader is cautioned not to place undue reliance on any forward-looking statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

    The Toronto Stock Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release. 



    Investor Relations Contact:
    
    Westwicke on behalf of Helius Medical Technologies, Inc.
    Jack Powell, Vice President
    [email protected]

    Primary Logo

    Get the next $TEVA alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TEVA
    $JNJ
    $BMY
    $HSDT

    CompanyDatePrice TargetRatingAnalyst
    Johnson & Johnson
    $JNJ
    9/23/2025$206.00Neutral → Buy
    Guggenheim
    Bristol-Myers Squibb Company
    $BMY
    8/5/2025$42.00Outperform → Neutral
    Daiwa Securities
    Johnson & Johnson
    $JNJ
    7/23/2025Hold → Buy
    Erste Group
    Teva Pharmaceutical Industries Limited
    $TEVA
    6/6/2025$24.00Buy
    Goldman
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/28/2025$25.00Buy
    Truist
    Johnson & Johnson
    $JNJ
    5/13/2025$153.00Outperform → Market Perform
    Leerink Partners
    Teva Pharmaceutical Industries Limited
    $TEVA
    5/12/2025$23.00Neutral → Overweight
    Analyst
    Bristol-Myers Squibb Company
    $BMY
    4/22/2025$55.00Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Preeminent SOL Treasury Company Helius (NASDAQ:HSDT) Announces Corporate Name Change to Solana Company and Letter of Intent with Solana Foundation

    HSDT Solana Company's Mission is to maximize SOL per share on one of the most commercially viable blockchains for consumer applications while delivering consistent on-chain yield for investors HSDT enters into agreement with the Solana Foundation to establish its collaboration and commit to joint initiatives This signifies HSDT's commitment to building a long-lasting institution that accelerates the growth of Solana and being a powerful advocate for Solana's development alongside the independent Solana Foundation and Solana Lab NEWTOWN, Pa., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (NASDAQ: HSDT) ("HSDT" or the "Company") announced that, following receipt of

    9/29/25 8:10:00 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    U.S. FDA approves TREMFYA® (guselkumab) for the treatment of pediatric plaque psoriasis and active psoriatic arthritis, marking a first and only approval for an IL-23 inhibitor

    TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six years and older, weighing at least 40 kg  Approval was based on PROTOSTAR study, which showed pediatric patients receiving TREMFYA® achieved high levels of skin clearance vs. placebo at Week 16 HORSHAM, Pa., Sept. 29, 2025 /PRNewswire/ --  Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) has approved TREMFYA® (guselkumab) for the treatment of children six years and older who also weigh at least 40 kg with moderate to severe plaque psoriasis (PsO), w

    9/29/25 8:00:00 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Teva Releases Q3 2025 Aide Memoire

    TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q3 2025 Aide Memoire is available on the "Investors" page on its website. Q3 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva's commitment has nev

    9/25/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    September 26, 2024 - FDA Approves Drug with New Mechanism of Action for Treatment of Schizophrenia

    For Immediate Release: September 26, 2024 Today, the U.S. Food and Drug Administration approved Cobenfy (xanomeline and trospium chloride) capsules for oral use for the treatment of schizophrenia in adults. It is the first antipsychotic drug approved to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care.   “Schizophrenia is a leading

    9/26/24 6:42:20 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    June 14, 2024 - FDA Roundup: June 14, 2024

    For Immediate Release: June 14, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued a proposed exemption for certain cottage cheese products from the requirements of the Food Traceability Rule. The proposal would exempt Grade “A” cottage cheese that appears on the Interstate Milk Shippers List from the requirements of the r

    6/14/24 3:54:45 PM ET
    $MMSI
    $BMY
    Medical/Dental Instruments
    Health Care
    Biotechnology: Pharmaceutical Preparations

    March 8, 2024 - FDA Roundup: March 8, 2024

    For Immediate Release: March 08, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced proposed new regulations to provide animal drug sponsors with predictable requirements for the labeling of prescription and over-the-counter new animal drugs, as well as new animal drugs for use in animal feeds. The proposed content and

    3/8/24 3:26:46 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, Chief Legal Officer Mcavoy David R. bought $20,988 worth of Ordinary Shares (1,113 units at $18.86), increasing direct ownership by 9% to 13,027 units (SEC Form 4)

    4 - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Issuer)

    9/9/25 4:02:56 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP,Chief Med.Offr.,Drug Dev. Hirawat Samit bought $202,215 worth of shares (4,250 units at $47.58), increasing direct ownership by 5% to 83,513 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    4/29/25 6:14:13 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Boerner Christopher S. bought $110,096 worth of shares (2,000 units at $55.05), increasing direct ownership by 2% to 104,626 units (SEC Form 4)

    4 - BRISTOL MYERS SQUIBB CO (0000014272) (Issuer)

    2/21/25 7:09:34 PM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Chee Choon Wee claimed ownership of 6,830,402 shares (SEC Form 3)

    3 - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Issuer)

    9/25/25 5:00:15 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    New insider Morikis John G claimed ownership of 599 shares (SEC Form 3)

    3 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/15/25 4:36:54 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Director Hewson Marillyn A

    4 - JOHNSON & JOHNSON (0000200406) (Issuer)

    9/11/25 5:52:29 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    SEC Filings

    View All

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Helius Medical Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Other Events, Financial Statements and Exhibits

    8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

    9/29/25 8:25:34 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

    9/25/25 9:00:18 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Helius Medical Technologies Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Filer)

    9/22/25 7:22:42 AM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    Johnson & Johnson upgraded by Guggenheim with a new price target

    Guggenheim upgraded Johnson & Johnson from Neutral to Buy and set a new price target of $206.00

    9/23/25 8:13:07 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol-Myers downgraded by Daiwa Securities with a new price target

    Daiwa Securities downgraded Bristol-Myers from Outperform to Neutral and set a new price target of $42.00

    8/5/25 7:09:09 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Johnson & Johnson upgraded by Erste Group

    Erste Group upgraded Johnson & Johnson from Hold to Buy

    7/23/25 8:55:43 AM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Teva Pharmaceutical Industries Limited

    SC 13G - TEVA PHARMACEUTICAL INDUSTRIES LTD (0000818686) (Subject)

    11/12/24 10:34:14 AM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Helius Medical Technologies Inc.

    SC 13G/A - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    11/8/24 5:12:24 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    SEC Form SC 13G filed by Helius Medical Technologies Inc.

    SC 13G - HELIUS MEDICAL TECHNOLOGIES, INC. (0001610853) (Subject)

    5/14/24 4:15:39 PM ET
    $HSDT
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Leadership Updates

    Live Leadership Updates

    View All

    Vicarious Surgical Announces Appointment of Joseph Doherty as Chairman of The Board

    Vicarious Surgical Inc. (NYSE:RBOT, RBOT.WS)) (the "Company"), a next-generation robotics technology company seeking to improve lives by transforming robotic surgery, today announced the appointment of Joseph Doherty as Chairman of the Company's Board of Directors (the "Board"). Mr. Doherty has served as a member of the Board since June 2025. "Since joining Vicarious Surgical, I've had the opportunity to work closely with Joe and greatly value his perspective," said Stephen From, Chief Executive Officer. "As Chairman of the Board, he brings a wealth of experience and thoughtful leadership that will serve the Company well. I look forward to partnering with him and the Board as we advance o

    9/25/25 4:15:00 PM ET
    $JNJ
    $RBOT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Industrial Specialties

    Johnson & Johnson Elects John Morikis, Retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, to its Board of Directors

    Johnson & Johnson (NYSE:JNJ) announced today that John Morikis, retired Chairman, President and Chief Executive Officer of The Sherwin-Williams Company, has been elected to its Board of Directors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250908666514/en/John Morikis headshot "We are pleased to welcome John to our Company's Board of Directors," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "He is a proven leader of a large multinational organization who possesses a strong understanding of global markets and complex supply chains. His unique perspective and ability to harness technology to driv

    9/8/25 6:17:00 PM ET
    $JNJ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cristian Massacesi, M.D., Joins Bristol Myers Squibb as Executive Vice President, Chief Medical Officer and Head of Development

    Dr. Massacesi will join BMS August 1 and serve on the Executive Leadership Team Samit Hirawat, M.D., Executive Vice President, to step down from his role on August 1 and will depart BMS on November 1 Bristol Myers Squibb (NYSE:BMY) today announced the appointment of Cristian Massacesi, M.D., as Executive Vice President, Chief Medical Officer, and Head of Development, effective August 1, 2025. In this role, Dr. Massacesi will oversee the company's early-stage and late-stage product development across all therapeutic areas. "We are thrilled to welcome Cristian to Bristol Myers Squibb," said Christopher Boerner, Ph.D., board chair and chief executive officer, Bristol Myers Squibb. "His d

    7/25/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $TEVA
    $JNJ
    $BMY
    $HSDT
    Financials

    Live finance-specific insights

    View All

    Teva to Host Conference Call to Discuss Third Quarter 2025 Financial Results at 8 a.m. ET on November 5, 2025

    TEL AVIV, Israel, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its third quarter 2025 financial results on Wednesday, November 5, 2025, at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin. A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations. Following the conclusion of the call, a replay of the webc

    9/25/25 4:30:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Long-term Safety Data from the Completed Phase 3 SOLARIS Trial Support the Potential of Olanzapine LAI (TEV-'749) as the First Long-Acting Olanzapine Treatment Option for Schizophrenia with No PDSS Observed

    Through Week 56 in the SOLARIS trial, there were no suspected or confirmed post-injection delirium/sedation syndrome (PDSS) events observed with olanzapine LAI (TEV-'749) and its long-term systemic safety profile was consistent with other olanzapine formulations1Additional new data comparing initiation of UZEDY® (risperidone) versus Invega Sustenna® (paliperidone palmitate) in hospitalized patients found that UZEDY was associated with shorter length of stay and was preferred overall by HCPs due to its dosing characteristics and ease of use1Teva is committed to researching and developing innovative medicines that help address unmet needs for individuals living with complex mental health condi

    9/20/25 10:15:00 PM ET
    $TEVA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Bristol Myers Squibb to Report Results for Third Quarter 2025 on October 30, 2025

    Bristol Myers Squibb (NYSE:BMY) will announce results for the third quarter of 2025 on Thursday, October 30, 2025. Company executives will review financial results with the investment community during a conference call beginning at 8:00 a.m. ET. Investors and the general public are invited to listen to a live webcast of the call at http://investor.bms.com. Materials related to the call will be available at http://investor.bms.com prior to the start of the conference call. A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. About Bristol Myers Squibb: Transforming Patients' Lives Through Science At Bristo

    9/19/25 6:59:00 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care